Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
US8389472B2 · kind B2 · utility
0Cited by
2References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 21, 2006 |
| Grant date | Mar 5, 2013 |
| Priority date | — |
| Expiry date | Mar 21, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.